Study of the Immune Response in Colon Adenocarcinoma

Clinical Trial Summary

Duration of each part of the study per patient: - Screening: From 1 to 4 weeks - Sampling period (blood and tissue): 1 day - Follow-up by patient: 60 months - Total study duration by patient: 84 months - Total inclusion duration: 24 months - Total Follow-up duration: 60 months - Total study duration: 84 months

See also
Status	Clinical Trial	Phase
Completed	`NCT04003181` - The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon	N/A
Active, not recruiting	`NCT04057274` - Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth	N/A
Completed	`NCT02127359` - Whole-Exome Sequencing (WES) of Cancer Patients
Completed	`NCT00096278` - Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer	Phase 3
Active, not recruiting	`NCT02912559` - Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair	Phase 3
Completed	`NCT02569723` - Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy	N/A
Recruiting	`NCT05746195` - Optimization of Adaptive Text Messages for Cancer Survivors (OATS II)	N/A
Active, not recruiting	`NCT03365882` - S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery	Phase 2
Completed	`NCT02393755` - Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT05710406` - Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer	Phase 2/Phase 3
Recruiting	`NCT06017141` - Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study	Phase 2
Active, not recruiting	`NCT03436563` - M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability	Phase 1/Phase 2
Recruiting	`NCT05482516` - Evaluating Novel Therapies in ctDNA Positive GI Cancers	Phase 3
Completed	`NCT02368886` - Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer	Phase 2
Active, not recruiting	`NCT02863107` - Young-Onset Colorectal Cancer
Active, not recruiting	`NCT04963283` - Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer	Phase 2
Completed	`NCT05872334` - The Safety and Feasibility of MONOFIX on Fascial Closure of Mid-line Wound After Minimally Invasive Colorectal Cancer Surgery	N/A
Completed	`NCT03949777` - Validation of Aer-O-Scope Colonoscope System Cecal Intubation	N/A
Completed	`NCT06216405` - Performance of Artificial Intelligence in Colonoscopy for Right Colon Polyp Detection	N/A
Recruiting	`NCT05186116` - LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis	N/A

NCT number	NCT03015038
Study type	Observational
Source	Institut National de la Santé Et de la Recherche Médicale, France
Contact
Status	Active, not recruiting
Phase
Start date	February 5, 2017
Completion date	February 2024

Study of the Immune Response in Colon Adenocarcinoma — IMCO

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms